Abstract
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and asthma are chronic type 2 inflammatory diseases. Dupilumab (DUP), a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4/-13, key and central drivers of type 2 inflammation. Omalizumab (OMZ) is a humanized, monoclonal antibody which blocks the action of IgE. Both DUP and OMZ are approved for the treatment of uncontrolled CRSwNP or nasal polyps and asthma. To contribute to evidence-based decision making for treating respiratory diseases, head-to-head studies are required to investigate the comparative efficacy and safety of these interventions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
